Medical specialists from Belgium tagged as investigators in clinical trials studying Carcinoma
Total 89 results
-
Patrick Neven, MDSeen in:
- Leuven, UZ Leuven
Trials:- NCT04551495 (Principal Investigator)
-
Paul ClementSeen in:
- Leuven, U.Z. Leuven - Campus Gasthuisberg
Trials:- NCT03088059 (Principal Investigator)
Conditions: -
Philip DebruyneSeen in:
- Kortrijk, AZ Groeninge - Campus Kennedylaan - account 2
- Kortrijk, AZ Groeninge Kortrijk - Campus Kennedylaan
Trials:- NCT03088059 (Principal Investigator)
- NCT05327530 (Principal Investigator)
-
Pierre FreresSeen in:
- Liege, CHU de Liège - PARENT
Trials:- NCT05327530 (Principal Investigator)
-
Pol SpecenierSeen in:
- Antwerpen, Universitair Ziekenhuis Antwerpen
- Edegem, Universitair Ziekenhuis Antwerpen
Trials:- NCT04211337 (Principal Investigator)
- NCT03088059 (Principal Investigator)
- NCT03235245 (Principal Investigator)
-
Renaud Poncin, MDSeen in:
- Brabant Wallon, Ottignies, Clinique Saint-Pierre
Trials:- NCT02139020 (Principal Investigator)
Conditions: -
Samuel Bral, MDSeen in:
- Brussels, Jette, UZ Brussel
Trials:- NCT00727350 (Principal Investigator)
Conditions: -
Sandra NuytsSeen in:
- Leuven, Radiation Oncology
- Leuven, U.Z. Leuven - Campus Gasthuisberg
- Leuven, Universitaire Ziekenhuizen Leuven
Trials:- NCT01827709 (Principal Investigator)
- NCT02984410 (Principal Investigator)
- NCT04688528 (Sub-Investigator)
-
Sandra Schmitz, MDSeen in:
- Brussels, Cliniques Universitaires Saint-Luc
Trials:- NCT02984410 (Principal Investigator)
-
Sarah CosynsSeen in:
- Gent, Ghent University Hospital
Trials:- NCT03779009 (Sub-Investigator)
- NCT04512209 (Sub-Investigator)
- NCT03772444 (Sub-Investigator)
-
Sébastien Van Der Vorst, MDSeen in:
- Yvoir, CHU Dinant Godinne
- Yvoir, Namur, CHU-UCL Namur - CHU Mont Godinne
Trials:- NCT02984410 (Principal Investigator)
- NCT02990936 (Principal Investigator)
-
Stéphanie Deheneffe, MDSeen in:
- Namur, CHU-UCL Namur
Trials:- NCT04688528 (Principal Investigator)
Conditions: -
Stéphanie Gabriel, MDSeen in:
- Namur, CHU-UCL Namur
Trials:- NCT04688528 (Sub-Investigator)
Conditions: -
Stephanie HenrySeen in:
- Namur, CHU UCL Namur
- Namur, CHU UCL Namur Site de Sainte-Elisabeth
- Namur, CHU UCL Namur, Site Sainte-Elisabeth
- Namur, CHU UCL Namur/Site Sainte Elisabeth
- Namur, Clinique et Maternité Sainte-Elisabeth
- Yvoir, CHU Dinant Godinne - UCL Namur
- Yvoir, GSK Investigational Site
Trials:- NCT04975308 (Principal Investigator)
- NCT03088059 (Principal Investigator)
- NCT05611931 (Principal Investigator)
- NCT06256588 (Principal Investigator)
- NCT03786081 (Principal Investigator)
- NCT02139020 (Principal Investigator)
- NCT03526835 (Principal Investigator)
Conditions:- Breast Neoplasms;
- Neoplasm Metastasis;
- Carcinoma, Squamous Cell of Head and Neck;
- Endometrial Cancer;
- Neoplasms, Head and Neck;
- Cervical Cancer;
- Squamous Cell Carcinoma of the Head and Neck;
- Gastric Cancer;
- Colorectal Cancer;
- NSCLC;
- Head and Neck Squamous Cell Carcinoma;
- HNSCC;
- Advanced/Metastatic Solid Tumors;
- Gastroesophageal-junction Cancer
-
Sylvie RotteySeen in:
- Gent, U.Z. Gent Medical Oncology
- Gent, UZ Gent
- Gent, Universitair Ziekenhuis Gent
- Gent, Universitair Ziekenhuis Gent - Medical Oncology
Trials:- NCT03088059 (Principal Investigator)
- NCT02834884 (Principal Investigator)
- NCT05327530 (Principal Investigator)
- NCT05159388 (Principal Investigator)
- NCT05848011 (Principal Investigator)
Conditions:- Carcinoma, Squamous Cell of Head and Neck;
- All Tumor Types;
- Locally Advanced or Metastatic Urothelial Carcinoma;
- Solid Tumor;
- Prostate Cancer Recurrent;
- Immunotherapy;
- Androgen-Independent Prostatic Cancer;
- Androgen-Resistant Prostatic Cancer;
- Hormone Refractory Prostatic Cancer;
- Immune Checkpoint Inhibitor;
- Androgen-Independent Prostatic Neoplasms;
- Androgen-Insensitive Prostatic Cance;
- Inhibitory Checkpoint Molecule
-
Thierry Berghmans, MDSeen in:
- Anderlecht, Institut Jules Bordet
- Brussel, Institut Jules Bordet
- Brussels, Department of Intensive Care Unit and Thoracic Oncology Institut Jules Bordet
- Brussels, Hopitaux Universitaires - Institut Jules Bordet
- Brussels, Institut Jules Bordet-Hopital Universitaire ULB
Trials:- NCT03368820 (Principal Investigator)
- NCT02834884 (Principal Investigator)
- NCT03134118 (Principal Investigator)
- NCT04790253 (Principal Investigator)
- NCT04127110 (Principal Investigator)
-
Thierry Gustot, MD PhDSeen in:
- Brussels, Free University of Brussels
Trials:- NCT05276037 (Principal Investigator)
Conditions: -
Thomas Vanwolleghem, MD PhDSeen in:
- Antwerpen, University Hospital, Antwerp
Trials:- NCT05276037 (Sub-Investigator)
Conditions: -
Toon Van GorpSeen in:
- Leuven, UZ Leuven
- Leuven, UZLeuven
Trials:- NCT05456685 (Principal Investigator)
- NCT05041257 (Principal Investigator)
- NCT05611931 (Principal Investigator)
-
Valerio LucidiSeen in:
- Brussels, Free University of Brussels
Trials:- NCT05276037 (Sub-Investigator)
Conditions: -
Vincent Vandecaveye, MD, PhDSeen in:
- Vlaams-Brabant, Leuven, University Hospitals UZ Leuven, Gasthuisberg
Trials:- NCT02051283 (Principal Investigator)
- NCT02425540 (Principal Investigator)
Conditions: -
Vincent Verschaeve, MDSeen in:
- Hainaut, Charleroi, (Grand Hopital de Charleroi) GHDC
Trials:- NCT05551117 (Principal Investigator)
Conditions:- Melanoma;
- Non-small Cell Lung Cancer;
- Small-cell Lung Cancer;
- Head and Neck Squamous Cell Carcinoma;
- Anal Cancer;
- Malignant Melanoma;
- Non-small Cell Carcinoma;
- Oral Squamous Cell Carcinoma;
- Small Cell Carcinoma;
- Laryngeal Squamous Cell Carcinoma;
- Carcinoma, Squamous Cell of Head and Neck;
- Castration-Resistant Prostatic Cancer;
- Androgen-Independent Prostatic Cancer;
- Androgen-Insensitive Prostatic Cancer;
- Androgen-Resistant Prostatic Cancer;
- Hormone Refractory Prostatic Cancer;
- Anal Neoplasm
-
Wesley TeurfsSeen in:
- Antwerpen, ZNA Middelheim - Middelheim - account 2
Trials:- NCT05327530 (Principal Investigator)
-
Wim DemeySeen in:
- Brasschaat, AZ KLINA Brasschaat
- Brasschaat, AZ Klina - PARENT
- Other, Brasschaat, Algemeen Ziekenhuis Klina
Trials:- NCT05512364 (Principal Investigator)
- NCT05327530 (Principal Investigator)
- NCT06012435 (Principal Investigator)
-
Yassine LalamiSeen in:
- Brussel, Hôpitaux Universitaires Bordet-Erasme - Institut Jules Bordet
Trials:- NCT03088059 (Principal Investigator)
Conditions:
Clinical Trials on Carcinoma
-
Eye & ENT Hospital of Fudan UniversityChanghai Hospital; Fudan University; RenJi Hospital; Xinhua Hospital, Shanghai... and other collaboratorsRecruitingGlottic Carcinoma | Supraglottic Carcinoma | Subglottic Carcinoma | Pyriform Sinus Carcinoma | Postcricoid Carcinoma | Posterior Pharyngeal Wall CarcinomaChina
-
Roswell Park Cancer InstituteIovance Biotherapeutics, Inc.WithdrawnMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Unresectable Renal Pelvis Urothelial Carcinoma | Unresectable Ureter Urothelial CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | Multicentric Breast Carcinoma | Multifocal Breast Carcinoma | Synchronous Bilateral Breast CarcinomaUnited States, France, Spain, Canada, Saudi Arabia, Puerto Rico, Korea, Republic of, Ireland, Colombia, Mexico
-
National Cancer Institute (NCI)CompletedRecurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Laryngeal Verrucous Carcinoma | Recurrent Oral Cavity Verrucous Carcinoma | Tongue... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingEstrogen Receptor Positive | Ductal Breast Carcinoma In Situ | Grade 1 Invasive Breast Carcinoma | Grade 2 Invasive Breast Carcinoma | Grade 3 Invasive Breast Carcinoma | Invasive Ductal and Lobular Carcinoma In Situ | Mucinous Breast Carcinoma | Tubular Breast CarcinomaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Locally Advanced Bladder Urothelial Carcinoma | Locally Advanced Renal Pelvis Urothelial... and other conditionsUnited States
-
National Cancer Institute (NCI)Not yet recruitingBreast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ | Estrogen Receptor-Positive Breast CarcinomaUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingCancer Survivor | Invasive Breast Carcinoma | Ductal Breast Carcinoma In SituUnited States
-
Stanford UniversityRecruitingSurgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma (NORDIS)Ductal Breast Carcinoma in SituUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedBreast Carcinoma | Recurrent Breast Carcinoma | Breast Ductal Carcinoma In Situ | Invasive Breast CarcinomaUnited States